Aptiv, Cancer Genetics Ink Partnership Directed at Cancer Clinical Trials | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Aptiv Solutions today announced a partnership with Cancer Genetics for products and services directed at oncology clinical trials.

The two firms did not specify what products or services will result from the deal, but Aptiv said in a statement that they will provide "biopharmaceutical firms with a better understanding of modes of action of a variety of therapeutics and the role of biomarkers in the oncology drug development process."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.